搜索到 1000 条关于 자ㅇ위녀영상 Ap131.top 자갈치걸불륜 덕소맘야설 임실녀리얼 sB 的文章

七夕节:话一话古代十大奇葩避孕方式

2016.08.09 七夕节:话一话古代十大奇葩避孕方式

CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401

2012.09.19 2010 第五届国际基因组学大会(ICG-V)

, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster

2012.09.19 2012 中国医疗器械高峰论坛

trials and regulatory affairs
A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
清醒麻醉下经皮内镜脓肿切除术可有效治疗胰腺脓肿

2014.11.26 清醒麻醉下经皮内镜脓肿切除术可有效治疗胰腺脓肿

急性胰腺炎(acute pancreatitis,AP)可分为间质水肿型及坏死型,其中后者可引起诸多并发症,并存在一定的死亡率,与死亡率相关的因素包括脏器衰竭及胰腺脓肿(infected pancreatic necrosis,IPN)。 AP早期患者主要死于脏器衰竭,称之为重型胰腺炎或爆发性胰腺炎,晚期死亡的主要

2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)

。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
高再荣教授专访:难治性甲状腺癌的治疗策略

2017.08.23 高再荣教授专访:难治性甲状腺癌的治疗策略

,包括碘 131 全身扫描、颈部超声、CT 和磁共振等;三是分子标志物的检测。以上都是评价 RAI 治疗效果的重要手段。在评估过程中,必须贯穿一个很重要的理念,即动态评估。因为评价疗效不是一次决定终身,而是应该根据碘 131 治疗的时间和病情变化进行动态分层。丁香园:目前,国际上对于 RAI 抵抗的标准还存在争议,对此
EMA 专家小组建议批准辉瑞乳腺癌药物Ibrance

2016.09.19 EMA 专家小组建议批准辉瑞乳腺癌药物Ibrance

幅上涨。Ibrance 在 2015 年 2 月获得美国食品和药物管理局批准,在最近的一个季度中,为辉瑞公司 131 亿美元的季度销售额贡献了约 5 亿美元
王肖原主任中医师

2016.06.30 王肖原主任中医师

王肖原,主任中医师。杭州市基层名中医,儿科疾病专家。浙江省中医药学会儿科分会常务委员及青年委员会副主任委员、萧山中医药学会理事。萧山跨世纪科技人才培养人选、杭州市新世纪「131」 优秀中青年人才第三层次培养人选、第三批全国优秀中医临床人才。一直在中医儿科临床工作,曾先后师从省级名老中医宣桂琪、国家级名老中医王霞芳
中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较

2014.03.17 中国与美国甲状腺结节与分化型甲状腺癌诊治指南比较

随着甲状腺癌发病率的上升,国内开始重视甲状腺结节及分化型甲状腺癌的治疗,并发布了最新的相关指南,该指南与美国国立综合癌症网络(NCCN)、美国甲状腺学会(ATA)指南相比,在甲状腺结节术前评估、手术方式、术后131I 治疗及促甲状腺激素(TSH)抑制治疗方面均更加贴近我国国情,尤其是增加了良性甲状腺结节的治疗建议
多次复发的甲亢病例一例

2011.10.20 多次复发的甲亢病例一例

手术治疗又颇为忌惮,是否须I131治疗或中医针灸治疗(据说传统医学在治疗甲亢方面有独特的疗效);3:如继续口服药物,方案如何调整?请各位老师、同仁赐教。曾春霞:患者心率、血压、血常规是否正常?如果反复发作,无碘131治疗禁忌症,本人还是会建议碘131治疗,不过一定要跟病人说明会引起甲减的副作用,并且有40
ICU扎心的九十九问,你能答对多少题?

2019.11.11 ICU扎心的九十九问,你能答对多少题?

剩余(BE)正常值为-3~+3mmol/L;21、代谢性酸中毒的最基本特征?答:代谢性酸中毒最基本的特征是血浆HCO3—浓度原发性减少,血浆SB、AB、BB均降低,BE负值增大
经典化疗方案之:非小细胞肺癌

2018.05.16 经典化疗方案之:非小细胞肺癌

结合紫杉醇 100 mg/m2 QW+卡铂 AUC 6 Q3W(nab-PC)或紫杉醇 200 mg/m2+卡铂 AUC 6 Q3W(sb-PC)治疗,首要研究
急性循环衰竭中国急诊临床实践专家共识

2016.04.21 急性循环衰竭中国急诊临床实践专家共识

SB)、实际碳酸氢根(AB)、动脉血氧饱和度(SaO2)和阴离子隙(AG)等。急性循环衰竭(休克)患者常见代谢性酸中毒及低氧血症。创伤性休克中碱剩余
EHRA/ESC 心脏起搏器和心脏再同步治疗指南

2014.10.17 EHRA/ESC 心脏起搏器和心脏再同步治疗指南

心动过缓 (SB 和 AV 传导阻滞 ) 的典型症状  
ICU九十九问

2014.08.19 ICU九十九问

~+3mmol/L;21、代谢性酸中毒的最基本特征?答:代谢性酸中毒最基本的特征是血浆HCO3—浓度原发性减少,血浆SB、AB、BB均降低,BE负值增大,在失代偿时pH
【用药问答】甲亢性心脏病患者的治疗首选?

2020.11.25 【用药问答】甲亢性心脏病患者的治疗首选?

【今日问答】甲亢性心脏病的老年患者,甲状腺功能亢进的治疗首选?A.复方碘溶液B.大剂量普萘洛尔C.抗甲状腺药物D.核素131I治疗E.立即行甲状腺手术解析...131I禁忌者(C);复方碘溶液仅在甲亢手术前和甲状腺危象时使用(A)。大剂量普萘洛尔对甲亢性心脏病有益,但非首选药物(B)。甲状腺手术为创伤性措施,非首选,但凡疑是
两位院士莅临霍普,与参会专家共同探讨「前沿科技与临床转化」

2019.03.14 两位院士莅临霍普,与参会专家共同探讨「前沿科技与临床转化」

成为治疗脑瘫的有效措施,给更多患者带来福音」。甲亢碘-131 治疗剂量再优化 颜兵 北京霍普医院院长、核医学科主任、中国非公立医疗机构协会甲状腺专业委员会副主任委员、中华医学会核医学分会治疗学组委员颜兵院长详细阐述了新技术在精准测量甲状腺体积、精准估算碘-131 有效半衰期、以及个体化碘-131 剂量再优化中的临床医学
上一页 1 2 3 ... 48 49 50 到第